Molecular Biology of Mycobacterium Tuberculosis

Shinnick, Thomas M.

doi:10.1007/978-1-4615-5987-0_3

Cited by 2 publications

(3 citation statements)

References 98 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More than that, antibiotic selectable markers do not provide selection for in vivo utilizations which are not desirable in a practical recombinant BCG-based immunotherapy/ vaccine especially because plasmid vector loss has been implicated in failure of recombinant BCG vaccine candidates (Edelman et al 1999;Mederle et al 2002). Some concerns about the introduction of genes that confer resistance to antituberculosis drugs into the mycobacteria have also limited the utilization of antibiotics as selectable markers (Shinnick 1997).…”

Section: Modifying Bcg Strainsmentioning

confidence: 99%

“…Other selectable markers include genes that confer resistance to chloramphenicol, gentamicin, thiostrepton, hygromycin, streptomycin, and sulfonamide. Superinfection immunity to mycobacteriophages L5 (Donnelly-Wu et al 1993), resistance to mercury (Baulard et al 1995), and genomic insertion of biosynthetic enzymes genes that allow growth of recombinant strains in the absence of specific nutrients (such as valine and uridine) (Shinnick 1997) have also been used as selectable markers in mycobacteria. However, several of these selection systems are not powerful enough to fight low-frequency events such as high background rate of mutation to resistance or the limited susceptibility of the mycobacteria to the agent (Shinnick 1997).…”

Section: Modifying Bcg Strainsmentioning

confidence: 99%

“…Superinfection immunity to mycobacteriophages L5 (Donnelly-Wu et al 1993), resistance to mercury (Baulard et al 1995), and genomic insertion of biosynthetic enzymes genes that allow growth of recombinant strains in the absence of specific nutrients (such as valine and uridine) (Shinnick 1997) have also been used as selectable markers in mycobacteria. However, several of these selection systems are not powerful enough to fight low-frequency events such as high background rate of mutation to resistance or the limited susceptibility of the mycobacteria to the agent (Shinnick 1997). More than that, antibiotic selectable markers do not provide selection for in vivo utilizations which are not desirable in a practical recombinant BCG-based immunotherapy/ vaccine especially because plasmid vector loss has been implicated in failure of recombinant BCG vaccine candidates (Edelman et al 1999;Mederle et al 2002).…”

Section: Modifying Bcg Strainsmentioning

confidence: 99%

See 2 more Smart Citations

Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer

Begnini

Buss

Collares

et al. 2015

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

In the past three decades, intravesical instillation of Mycobacterium bovis bacille Calmette-Guérin (BCG) has been used for treating bladder cancer and it still remains at the forefront of immunotherapy for cancer patients. Although BCG-based therapy is the most effective intravesical therapy for this kind of tumor and represents the only agent known to reduce progression into muscle invasive bladder cancer, BCG is ineffective in approximately 30-40 % of cases and disease recurs in up to 50 % of patients. Since that BCG is considered an effective vehicle for delivery of antigens due to its unique characteristics, the genetic manipulation of these mycobacteria has been appealing in the search for less toxic and more potent therapeutic agents for bladder cancer immunotherapy. Herein, we discuss current advances in recombinant BCG construction, research, concerns, and future directions to promote the development of this promising immunotherapeutic approach for bladder cancer.

show abstract

Section: Modifying Bcg Strainsmentioning

confidence: 99%